Randomized clinical trial: efficacy of a food supplement, TRANSITECH, on healthy individuals with mild intermittent constipation.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

To investigate the effects of TRANSITECH, a food supplement composed of plants and lactic ferments, on bowel movements, CTT and bloating.

Why It Was Studied

Constipation is a common disorder in the general population and can be observed in healthy individuals.

Who Took Part

The abstract describes 100 participants taking part.

By PubMed's age tags, the people studied were young adults and adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

Their CTTs were also evaluated by following the propagation of radiopaque markers at D0 and D10.

What Was Measured

PubMed files the paper under topics including Bifidobacterium longum, Complex Mixtures, Constipation, Defecation, Dietary Supplements, Fermentation and France.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 100 participants.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2016 (European journal of gastroenterology & hepatology), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.